Rabinder Prinjha's Biography

Rabinder Prinjha, Vice President, GlaxoSmithKline

Rab Prinjha currently leads the Epinova Epigenetics DPU in the Immuno-Inflammation therapy area (II-TA) and is co-chair of the GSK Biology Council. Prior to this he led the Target Progression department with responsibilities for target selection, validation and epigenetic compound characterisation along with coordinating academic collaborations. He joined Epinova from the II-virtual group which was responsible for implementing the externalisation and portfolio diversification strategy of the TA. Previously he led a Target Validation group in the Neurology CEDD focussed on neurodegeneration. In addition to advancing many programs while in Neurology he cloned a novel inhibitor of CNS regeneration called Nogo-A and led this program from gene cloning to Candidate Selection and into clinical trials. Rab joined GSK from academia including a post-doc in developmental neuroscience at Guy’s Hospital and PhD in molecular biology of the cell cytoskeleton at UCL.